Switzerland’s Novocure Ltd (NASDAQ: NVCR) just revealed that its non-small cell lung cancer treatment device has received a certification for complying with European Union standards. Shares rose by 6 per cent during Tuesday’s trading session on the Nasdaq as a result.
The company’s Optune Lua gadget, which fights against lung cancer tumours with electric field technology, now has the CE (Conformité Européenne) Mark. Products being sold within the European Economic Area must have this symbol on them.
The news follows Novocure securing FDA approval for the medical device in October. Optune Lua is primarily intended to help patients that have been unsuccessful with chemotherapy treatment.
“The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant milestone in Novocure’s efforts to improve outcomes for people living with aggressive cancers,” President Frank Leonard said in a press release.
Novocure’s team recently attended the European Lung Cancer Congress 2025 event in Paris, France and educated attendees about the Tumour Treating Fields technology used in its therapeutic medical machine. This visit occurred at the end of March. The public oncology company has been gaining popularity throughout Europe.
$NVCR
Novocure, akciğer kanser tedavisinde kullanılacak yeni cihazı için AB'den onay aldı— Eray YILDIZ (@NasdaqSmallCaps) April 22, 2025
Read more: Breath Diagnostics onboards new president and closes critical financing
Read more: Breath Diagnostics pioneers novel lung cancer breath test
Novocure receives European award
This month, for the fourth time, the Swiss cancer treatment operator was recognized as a top company by the Austrian employer review platform Kununu. It is the largest in Europe.
Kununu praised Novocure for the efficient nature of its operations in Austria, Switzerland and Germany.
“A big thank you to all our employees,” Novocure said on LinkedIn, “you are at the core of what makes us a top company!”
For 2024, Novocure’s revenue rose by 19 per cent year-over-year to US$605.2 million. However, in Q4 the company reported a net loss of US$65.9 million and loss per share of US$0.61. Analysts have praised Novocure’s revenue growth and cash position (US$959.9 million) but have predicted that hefty R&D expenses will render the oncology tech developer unprofitable for the remainder of the year.
Novocure rang the opening bell at the Nasdaq Exchange in February to celebrate 25 years since its founding.
Optune Lua. Image credit: Novocure
Read more: Novocure scoops FDA approval for electric field lung cancer treatment device
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
